Skip to main content
. Author manuscript; available in PMC: 2021 Aug 27.
Published in final edited form as: Cell Metab. 2020 Aug 6;32(3):391–403.e6. doi: 10.1016/j.cmet.2020.07.009

Figure 6. Human Chemoresistant AML Cells Are Sensitive to Single-Dose, Timed Inhibition of Pyrimidine Synthesis.

Figure 6.

(A) Characteristics of the PDX lines.

(B–D) Percentage of human cells in the peripheral blood (B), bone marrow (C), or spleen weights (D) of PDX-engrafted mice treated sequentially with iCT (5 days of cytarabine 50 mg/kg + 3 days of doxorubicin 1.5 mg/kg i.v.) and/or Brequinar (BRQ, 25 mg/kg i.p.; given at day 2 after iCT), determined at day 4 after iCT. n = 4–5 mice per group. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.